1110007L15Rik Inhibitors
Chemical inhibitors of protein kinases can modulate the activity of 1110007L15Rik by targeting the signaling pathways that regulate its function. Staurosporine is a broad-spectrum kinase inhibitor which, by inhibiting various kinases, can reduce the phosphorylation and subsequent activation of 1110007L15Rik. Similarly, Bisindolylmaleimide I specifically inhibits protein kinase C (PKC), which is known to control numerous proteins, including 1110007L15Rik. By inhibiting PKC, Bisindolylmaleimide I can decrease the activity of 1110007L15Rik if it is regulated by PKC-mediated phosphorylation. LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinases (PI3K) and can reduce the activation of 1110007L15Rik by impeding the PI3K signaling pathway. If 1110007L15Rik is a downstream target of PI3K, then its activity would be decreased by these inhibitors.
Furthermore, PD98059 and U0126 are inhibitors of mitogen-activated protein kinase kinase (MEK) and, by extension, can suppress extracellular signal-regulated kinase (ERK) signaling. If 1110007L15Rik is regulated by the MEK/ERK pathway, these inhibitors can reduce its functional activity. SB203580, targeting p38 MAP kinase, and SP600125, inhibiting c-Jun N-terminal kinase (JNK), can each lead to reduced activity of 1110007L15Rik if it is part of their respective signaling cascades. Inhibition of the mTOR pathway by Rapamycin would also lead to a decrease in 1110007L15Rik activity if it is mTOR-dependent. Additionally, PP2, as a selective inhibitor of Src family tyrosine kinases, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can diminish the functional activity of 1110007L15Rik by preventing activation by Src kinases or Abl. Lastly, Lapatinib, which inhibits the tyrosine kinase domains of EGFR and HER2, can also reduce the activity of 1110007L15Rik if it is a downstream effector of EGFR/HER2 signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting a wide range of kinases that may phosphorylate 1110007L15Rik, staurosporine can reduce the phosphorylation-dependent activation of this protein. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). Given that 1110007L15Rik's activity is regulated by PKC-mediated signaling, inhibition of PKC would lead to a decrease in 1110007L15Rik's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If 1110007L15Rik is downstream of PI3K signaling, its inhibition would result in a decrease in 1110007L15Rik's functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It prevents PI3K from phosphorylating and activating downstream targets, which would include 1110007L15Rik if it is part of the PI3K/Akt pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK). Inhibition of MEK would lead to a decrease in ERK pathway signaling, potentially diminishing the activity of 1110007L15Rik if it is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also an inhibitor of MEK. By preventing MEK from activating ERK, U0126 can inhibit the function of proteins like 1110007L15Rik that may be controlled by the MEK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. If 1110007L15Rik is a downstream effector in the p38 MAPK pathway, then inhibiting p38 would directly reduce the functional activity of 1110007L15Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK inhibition can lead to reduced functional activity of downstream targets, including 1110007L15Rik, if it is a part of JNK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway. If 1110007L15Rik is regulated by mTOR-dependent signaling, its inhibition would decrease the functional activity of 1110007L15Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If 1110007L15Rik is activated by Src kinase signaling, inhibition by PP2 would decrease its functional activity. | ||||||